+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas



Role of thyroid transcription factor-1 and P63 immunocytochemistry in cytologic typing of non-small cell lung carcinomas



Journal of the Egyptian National Cancer Institute 25(4): 209-218



Evaluation of the value of thyroid transcription factor (TTF-1) and P63 in subtyping of non-small cell lung cancer in cytologic material. This is a retrospective study including 40 cases of primary lung lesions who underwent image guided FNAC from pulmonary nodules. The final histopathologic diagnosis was the gold standard. Cell blocks were stained with anti-TTF-1, and P63. Nuclear immunoreactivity for both markers was considered specific. Sensitivity, specificity, positive and negative predictive values, of the cytologic diagnosis and of the two markers, as well as the accuracy of the combined markers were calculated. Cytomorphology achieved a sensitivity of 83.3%, specificity of 91%, PPV of 91%, and NPV of 83.3%, for the diagnosis of AC, and 91% sensitivity, 83.3% specificity, 83.3% PPV, and 91% NPV, for the diagnosis of SCC. The concordance between cytologic and histopathologic diagnoses of AC and SCC was 87%. TTF-1 achieved 87.5% sensitivity, 94.7% specificity, 95.5% PPV, and 85.7% NPV for AC, while P63 achieved 94.7% sensitivity, 95.8% specificity, 94.7% PPV, and 95.8% NPV for SCC. TTF-1 enhanced the sensitivity of cytomorphology for AC from 83.3% to 87.5%, and specificity from 91% to 94.7%. Similarly P63 enhanced the sensitivity for SCC from 91% to 94.7%, and specificity from 83.3% to 95.8%. TTF-1 achieved moderate sensitivity, and high specificity in the diagnosis of AC, while P63 was highly sensitive and specific for the diagnosis of SCC. Immunocytochemistry raised the sensitivity and specificity of FNAC in diagnosing AC and SCC using TTF-1 and P63, respectively.

(PDF emailed within 0-6 h: $19.90)

Accession: 055614865

Download citation: RISBibTeXText

PMID: 24207093

DOI: 10.1016/j.jnci.2013.05.005


Related references

Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. American Journal of Surgical Pathology 24(9): 1217-1223, 2000

Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. American Journal of Surgical Pathology 25(3): 363-372, 2001

ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. Journal of Thoracic Oncology 7(2): 281-290, 2012

Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Letters 162(1): 97-103, 2000

Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Letters 162(1): 97-103, January 10, 2001

Comparison of immunohistochemistry and mRNA iin situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue. Oncology Letters 10(6): 3581-3584, 2016

Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases. Human Pathology 54: 8-16, 2016

Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Applied Immunohistochemistry & Molecular Morphology 10(2): 103-109, 2002

Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology (Oxford) 36(5): 415-420, 2000

Prognostic role of thyroid transcription factor-1 in stage III non-small cell lung cancer. Lung Cancer 52(2): 219-224, 2006

An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer. Journal of Pathology, 2018

Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Archives of Pathology & Laboratory Medicine 125(2): 228-231, 2001

Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. Journal of Pathology 198(2): 142-156, 2002

Thyroid transcription factor-1 and cytokeratin 1, 5, 10, 14 expression in basaloid and large cell neuroendocrine carcinomas of the lung. Laboratory Investigation 81(1): 222A, January, 2001

Thyroid transcription factor-1 is of limited value in practical distinction between pulmonary and extrapulmonary small cell carcinomas. American Journal of Surgical Pathology 25(4): 545-546, 2001